Core Viewpoint - Annexon, Inc. has initiated an underwritten public offering of $125 million in common stock, with an additional option for underwriters to purchase up to $18.75 million more, aimed at advancing its clinical platform for neuroinflammatory diseases [1][2]. Company Overview - Annexon is a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye [5]. - The company's approach targets upstream C1q to inhibit the classical complement inflammatory cascade, with therapeutic candidates showing promise in conditions such as Guillain-Barré syndrome, Huntington's disease, and geographic atrophy [5]. Offering Details - The public offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on April 1, 2024 [3]. - The offering will be made through a prospectus supplement and the accompanying prospectus, which will be available on the SEC's website [3].

Core Viewpoint - Annexon, Inc. has initiated an underwritten public offering of $125 million in common stock, with an additional option for underwriters to purchase up to $18.75 million more, aimed at advancing its clinical platform for neuroinflammatory diseases [1][2]. Company Overview - Annexon is a biopharmaceutical company focused on developing novel therapies for classical complement-mediated neuroinflammatory diseases affecting the body, brain, and eye [5]. - The company targets upstream C1q to inhibit the classical complement inflammatory cascade, with therapeutic candidates showing promise in conditions such as Guillain-Barré syndrome, Huntington's disease, and geographic atrophy [5]. Offering Details - The public offering is being conducted under a shelf registration statement filed with the SEC, which was declared effective on April 1, 2024 [3]. - The offering will be made through a prospectus supplement and accompanying prospectus, which will be available on the SEC's website [3]. Underwriters - The joint book-running managers for the offering include J.P. Morgan, Jefferies, TD Cowen, BofA Securities, and Wells Fargo Securities [2].

Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Comparability Data Expected in First Half 2025 Conference call and web ...

BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data. Conference Call and Webcast InformationThe live webcast and replay may be accessed by visiting Annexon’s website here. The dial-in nu ...

BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data. Conference Call and Webcast InformationThe live webcast and replay may be accessed by visiting Annexon's website here. The dial-in num ...

A downtrend has been apparent in Annexon, Inc. (ANNX) lately with too much selling pressure. The stock has declined 5% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spo ...

BRISBANE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on May 11, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the new ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ANNX The Nasdaq Stock Market LLC FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURIT ...

Exhibit 99.1 Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones Multiple Value-creating Catalysts Across the Annexon Portfolio Throughout 2024 Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024; Potential to be the First Targeted Treatment for GBS New Phase 2 Data Showing Neuroprotection of Vision and Vision-Associated Structures by ANX007 in Geographic Atrophy (GA) Presented at ARVO 2024; Initiation of Pivotal Phase 3 ANX007 ARC ...

ANX007 demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings ANX007 protected key retinal structures important for vision: significant reduction of photoreceptor loss and meaningful slowing of lesion growth measured by retinal pigment epithelium (RPE) loss in the fovea C1q blockade protected photoreceptor synapses and preserved retinal function in preclinical model, supporting the mechanistic understanding of ANX007 in preserving syna ...